The post Base App is Ending Creator Rewards: Trading-Focused Transformation appeared on BitcoinEthereumNews.com. Coinbase’s “Everything App” Base App is shiftingThe post Base App is Ending Creator Rewards: Trading-Focused Transformation appeared on BitcoinEthereumNews.com. Coinbase’s “Everything App” Base App is shifting

Base App is Ending Creator Rewards: Trading-Focused Transformation

Coinbase’s “Everything App” Base App is shifting to a strategy fully focused on tradable assets by ending the Creator Rewards program and the Farcaster-supported social feed. The Creator Rewards program, launched in July, aimed to turn Ethereum layer 2 Base into a social ecosystem and distributed a total of 450 thousand dollars to 17 thousand creators over seven months, providing an average earnings of 26 dollars. In a statement from Base App’s X account, Base creator Jesse Pollak emphasized that the app’s sole focus should be trading.


Source: Base App

Details and End of Base App Creator Rewards Program

The program will end on Sunday, and final payments will be made on February 18. This decision marks Base App’s move away from social features just two months after its official launch in December. Creator Rewards was designed to incentivize content creators, but the low average earnings (26 USD per person) show that social integration did not overshadow trading traffic. This pivot is a critical step in the maturation process of the Base ecosystem.

Program Performance: Analysis with Numbers

450,000 USD was distributed to 17,000 creators in seven months. Average earnings of 26 USD reveal that the program’s mass appeal remained limited. Comparatively, earnings were higher in similar Web3 social programs (e.g., Friend.tech). These figures justify Base App’s focus on financial tools rather than social features.

  • Total creators: 17.000
  • Total distribution: 450.000 USD
  • Average earnings: 26 USD/creator
  • Duration: July 2025 – February 2026

Jesse Pollak’s Strategic Statement

Base’s founder Jesse Pollak defended the direction change by saying, ‘The app’s sole focus needs to be trading.’ Pollak’s vision positions Base App as an ETH detailed analysis platform. The confession ‘We are not the perfect client for Farcaster’ predicts that users will turn to native clients like Warpcast.

Future of Farcaster and Creator Coins

The Farcaster social feed is being removed, but the Creator Coins program continues. These ERC-20 based tokens will remain integrated with Zora, protecting the creator economy. This distinction strengthens Base App’s hybrid structure: Not social, tradable assets take center stage.

Coinbase Everything App Vision and Base-ETH Connection

The change aligns with Coinbase’s vision of spot crypto, derivatives trading, stablecoins, and RWA tokenization. As an ETH Layer-2, Base increases ETH futures transactions volume. For the ETH ecosystem, Base App is becoming a liquidity hub.

Current ETH Market Analysis: Impact of Base Decision on ETH

Base’s trading-focused transformation may support ETH demand. As of February 10, 2026, ETH: 2.092,73 USD (+%0,18). RSI 31,85 (oversold), downtrend continues. Supertrend bearish, EMA20: 2.416,78 USD.

SupportsLevel (USD)ScoreDistanceSources
S11.747,8070/100 ⭐-16,48%Fibo 0.000, Donchian Lower
S21.917,0869/100 ⭐-8,39%ATR Lower, Fibo
ResistancesLevel (USD)ScoreDistanceSources
R12.147,5975/100 ⭐+2,62%R3, Prev Day High, Fibo
R22.575,3673/100 ⭐+23,06%Ichimoku Senkou B

Base App’s focus could test the R1 resistance by increasing ETH L2 TVL.

Senior Technical Analyst: James Mitchell

6 years of crypto market analysis

This analysis is not investment advice. Do your own research.

Source: https://en.coinotag.com/base-app-is-ending-creator-rewards-trading-focused-transformation

Market Opportunity
RWAX Logo
RWAX Price(APP)
$0.0001417
$0.0001417$0.0001417
+0.99%
USD
RWAX (APP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26